Wegovy vs Liraglutide: Long-Term Durability of Response

How Much Weight Does Each Drug Actually Produce?

Semaglutide 2.4 mg consistently outperforms liraglutide 3.0 mg on absolute and percentage weight loss across every head-to-head comparison in the literature. The difference is not marginal. It averages 6 to 7 percentage points of body weight across the major randomized trials, which translates to roughly 6 to 9 kg in a 90 kg patient.

STEP-1: The Semaglutide Benchmark

STEP-1 (N=1,961, 68 weeks) is the registration trial for Wegovy. Patients without diabetes assigned to semaglutide 2.4 mg lost a mean of 14.9% of body weight versus 2.4% with placebo (P<0.001). More than 86% of participants on semaglutide achieved at least 5% weight loss, and 50% achieved at least 15% [1]. These results established semaglutide 2.4 mg as the most effective approved GLP-1 receptor agonist for obesity at the time of its approval.

SCALE Obesity: The Liraglutide Benchmark

SCALE Obesity (N=3,731, 56 weeks) established liraglutide 3.0 mg as a meaningful obesity therapy. Mean weight loss was 8.4% on liraglutide versus 2.8% on placebo (P<0.001) [2]. Approximately 63% of liraglutide patients achieved at least 5% weight loss, compared with 27% on placebo. The trial population included patients with BMI <30 kg/m² with at least one weight-related comorbidity, making direct comparison with STEP-1 imperfect but directionally informative.

Direct Head-to-Head Evidence

A 2022 network meta-analysis published in JAMA evaluated 143 randomized controlled trials (N=49,810) covering multiple obesity pharmacotherapies. Semaglutide 2.4 mg produced the greatest percentage weight loss of all approved agents, including liraglutide, phentermine-topiramate, and naltrexone-bupropion [3]. The authors concluded that "semaglutide 2.4 mg was associated with the largest reduction in body weight" among all included interventions. No direct randomized trial has compared the two agents head-to-head in a single study population, but indirect comparisons consistently favor semaglutide by a clinically meaningful margin.

Long-Term Durability: Who Holds Weight Loss Over Time?

Durability is a different question from peak efficacy. A drug might produce strong initial losses that attenuate, or it might maintain losses steadily. Both semaglutide and liraglutide show weight regain after discontinuation, but the magnitude and trajectory differ.

Semaglutide Durability Data

The STEP-4 trial (N=803) provides the clearest window into semaglutide durability. Patients who completed 20 weeks on semaglutide 2.4 mg (achieving a mean 10.6% weight loss) were randomized either to continue semaglutide or switch to placebo for an additional 48 weeks. Those who continued semaglutide lost an additional 7.9% of body weight. Those switched to placebo regained 6.9% [4]. The data show that continued treatment is required to maintain weight loss. Durability is drug-dependent, not self-sustaining.

In a 2-year extension of STEP-1, patients who remained on semaglutide maintained approximately 15% weight loss through 104 weeks, with no meaningful attenuation of effect [5]. That is a 2-year durability signal that no comparable liraglutide dataset matches in sample size or duration.

Liraglutide Durability Data

The SCALE Maintenance trial (N=422) enrolled patients who had already lost at least 5% of body weight through a low-calorie diet and then randomized them to liraglutide 3.0 mg or placebo for 56 weeks. Liraglutide maintained a 6.2% additional weight loss versus placebo [6]. This trial demonstrates that liraglutide can preserve weight loss once achieved, but the absolute numbers remain below what semaglutide delivers in its own maintenance data.

Real-world persistence data for liraglutide are concerning. A retrospective cohort study using U.S. Claims data found that only about 35% of patients prescribed liraglutide 3.0 mg remained on therapy at 12 months [7]. Lower persistence reduces real-world durability independent of the pharmacological effect.

What Happens When Either Drug Is Stopped?

Both agents show similar patterns after discontinuation: patients regain weight relatively quickly. A 2022 analysis published in Diabetes, Obesity and Metabolism found that patients stopping liraglutide 3.0 mg regained approximately 50% of their lost weight within 12 weeks and approached baseline body weight by 52 weeks [8]. Semaglutide shows similar post-discontinuation rebound in STEP-4 data. Obesity is a chronic disease, and neither agent produces durable weight loss independent of continued pharmacotherapy.

GI Tolerability and Adverse Effects

Both drugs act on GLP-1 receptors in the gut, and both produce overlapping GI side effects. The difference lies in frequency and manageability.

Nausea and Vomiting Rates

In STEP-1, nausea occurred in 44% of semaglutide patients versus 16% with placebo. Vomiting occurred in 24% versus 6% [1]. In SCALE Obesity, nausea occurred in 39.3% of liraglutide patients and vomiting in 14.8% [2]. Rates are broadly comparable, though the once-weekly dosing of semaglutide may concentrate GI burden to a predictable 24 to 48-hour window after injection rather than spreading it across daily injections.

Discontinuation Due to Adverse Events

In STEP-1, 7.0% of semaglutide patients discontinued due to adverse events versus 3.8% on placebo [1]. In SCALE Obesity, 9.9% of liraglutide patients discontinued versus 3.8% on placebo [2]. Liraglutide shows a marginally higher discontinuation rate from GI events, which may reflect daily dosing frequency rather than intrinsic pharmacological differences.

Injection Burden

One injection per week versus one injection per day is a meaningful practical difference. Patients on liraglutide complete 365 injections per year. Patients on semaglutide complete 52. This matters for adherence, needle fatigue, and injection-site reactions. No direct trial has randomized patients to compare adherence by dosing frequency alone, but adherence data across GLP-1 agents generally favor less frequent dosing schedules.

Cost, Generic Availability, and Insurance Access

Liraglutide Generic Status

As of mid-2025, no FDA-approved generic liraglutide 3.0 mg product has reached commercial market. Novo Nordisk holds patents on Saxenda through the mid-2020s, and while biosimilar development is underway, no biosimilar has received FDA approval for the weight-management indication specifically. Patients hoping for cost savings from a liraglutide generic should be aware that this option remains unavailable in the United States [9].

Branded Pricing

Wegovy carries a list price of approximately $1,349 per month without insurance. Saxenda lists at approximately $1,349 to $1,400 per month. Both prices are nearly identical at list. Insurance coverage varies substantially. Many commercial plans now cover Wegovy with prior authorization for BMI <30 kg/m² plus a comorbidity, or BMI <35 kg/m² without comorbidity. Saxenda coverage patterns are similar but increasingly redirected to semaglutide as first-line on formulary.

Cost-Effectiveness

A 2023 cost-effectiveness analysis from the NEJM Evidence group estimated that semaglutide 2.4 mg at current list price exceeded standard thresholds for cost-effectiveness in the U.S. Healthcare context unless used in patients with the highest cardiovascular risk [10]. Liraglutide has a similar cost-effectiveness profile. If a generic liraglutide does reach market at substantially lower cost, the calculus may shift for patients without insurance coverage for either branded agent.

Switching Between Wegovy and Liraglutide

Why Patients Switch

Switches from Wegovy to liraglutide happen for three main reasons: insurance coverage loss, supply chain disruption, or cost. Switches in the opposite direction (liraglutide to Wegovy) happen because of inadequate weight loss response or patient preference for weekly dosing.

How to Switch From Liraglutide to Semaglutide

The Endocrine Society and AACE do not publish a standardized switching protocol for these two specific agents, but clinical practice generally follows this approach: stop liraglutide and start semaglutide 0.25 mg subcutaneously once weekly with a standard 16-week titration to 2.4 mg. Because both drugs act at the GLP-1 receptor, there is no pharmacological washout period required. Overlapping coverage at the receptor level may theoretically reduce initial GI side effects during transition, but no trial has studied this directly [11].

How to Switch From Wegovy to Liraglutide

This is the more clinically consequential direction. Patients switching from semaglutide 2.4 mg to liraglutide 3.0 mg should expect weight regain. The pharmacological gap between the two agents means liraglutide cannot fully maintain the weight losses achieved on semaglutide. A reasonable expectation is partial maintenance: liraglutide may preserve some of the loss but will not sustain all of it. Starting liraglutide at 0.6 mg daily and titrating to 3.0 mg over 5 weeks is the standard approach per the Saxenda prescribing information [12].

HealthRX Clinical Switching Framework: Wegovy to Liraglutide

| Patient Situation | Expected Outcome | Clinical Recommendation | |---|---|---| | Insurance gap, temporary | Partial weight regain likely | Bridge with liraglutide, plan to resume semaglutide | | Intolerance to semaglutide GI effects | Variable; daily dosing may worsen GI burden | Trial period with liraglutide at lowest titration; reassess at 12 weeks | | Cost-driven permanent switch | Mean 5 to 7% weight regain expected within 6 months | Discuss expectations before switching; explore patient assistance programs first | | Inadequate response on liraglutide | Semaglutide upgrade appropriate | Switch to semaglutide 0.25 mg weekly; no washout needed |

Cardiovascular Outcomes: Does Durability Extend to Hard Endpoints?

Semaglutide Cardiovascular Data

The SELECT trial (N=17,604) tested semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide reduced the rate of major adverse cardiovascular events (MACE) by 20% versus placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90) over a median 34.2 months [13]. This is the first weight-management pharmacotherapy to demonstrate cardiovascular mortality benefit in a large outcomes trial.

Liraglutide Cardiovascular Data

The LEADER trial (N=9,340) tested liraglutide 1.8 mg (the diabetes dose, not the 3.0 mg obesity dose) in patients with type 2 diabetes and high cardiovascular risk. Liraglutide 1.8 mg reduced MACE by 13% versus placebo (HR 0.87, 95% CI 0.78 to 0.97) [14]. No equivalent large outcomes trial has been completed with liraglutide 3.0 mg in a non-diabetic obesity population.

The cardiovascular evidence base is substantially deeper and more recent for semaglutide at the weight-management dose, which matters when choosing between agents in patients with known or high-risk cardiovascular disease.

Who Should Use Which Drug?

Patients Best Suited for Semaglutide 2.4 mg

Patients with BMI <35 kg/m² plus a cardiovascular comorbidity, or BMI <40 kg/m² seeking maximum efficacy, are the clearest candidates for Wegovy. The SELECT cardiovascular benefit, the superior weight loss magnitude, and the weekly dosing schedule all support semaglutide as first-line where insurance and cost allow.

Patients Who May Benefit From Liraglutide

Patients who have failed semaglutide due to specific side effects, those requiring a lower starting dose for GI sensitivity, or those in whom cost constraints make Saxenda more accessible may still benefit meaningfully from liraglutide. An 8.4% mean weight loss is clinically significant. Reducing blood pressure, improving glycemia, and lowering triglycerides are achievable outcomes with liraglutide even if the magnitude falls short of semaglutide.

Patients With Type 2 Diabetes

Both drugs are approved at separate doses for type 2 diabetes management (semaglutide as Ozempic at 0.5 to 2.0 mg; liraglutide as Victoza at 1.2 to 1.8 mg). The obesity doses are distinct from the diabetes doses. In a patient with both obesity and type 2 diabetes seeking weight-management dosing, semaglutide 2.4 mg has the stronger evidence base and the SELECT cardiovascular data supporting long-term use.

Practical Dosing and Titration Comparison

Both drugs require slow titration to minimize GI side effects. The schedules differ in duration and steps.

Semaglutide 2.4 mg (Wegovy) titration:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Liraglutide 3.0 mg (Saxenda) titration:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance)

Semaglutide takes 16 weeks to reach maintenance dose. Liraglutide reaches maintenance in 5 weeks but requires daily commitment from day one. Patients who struggle with daily injections may not tolerate liraglutide titration long enough to see meaningful results.

Real-World Adherence and Persistence

Adherence Rates

Real-world adherence to GLP-1 receptor agonists for obesity is lower than in trial settings. A 2023 retrospective analysis using Optum claims data (N=12,800) found 12-month persistence rates of approximately 42% for semaglutide 2.4 mg and 33% for liraglutide 3.0 mg [7]. Both rates fall well below the 80% threshold typically cited for adequate chronic disease management, but semaglutide shows a statistically meaningful persistence advantage.

Why Persistence Matters for Durability

Durability of weight loss cannot be separated from durability of treatment. A drug that produces 14.9% weight loss in a trial but is discontinued by 65% of real-world patients within 12 months delivers a population-level benefit substantially smaller than the trial number suggests. The persistence advantage of semaglutide compounds its already superior trial efficacy to widen the real-world gap further.